← Back to Knowledge Base

Primary topic: SLCO1B1 gene cholesterol and blood-fat handling

SLCO1B1 Gene and Metabolism: What It Can Mean in a Pathway Report

SLCO1B1 is tracked because it connects to lipoprotein transport, triglyceride-rich particles, LDL clearance, or liver lipid handling. The current evidence index links this gene to Lipids with 1 SNP and 1 curated claim.

What is the SLCO1B1 gene?

Hepatic OATP1B1 transporter for statins and endogenous anions relevant to lipid pharmacogenomics.

How SLCO1B1 affects metabolism

When SLCO1B1-related function is shifted, the practical effect is interpreted through lipoprotein transport, triglyceride-rich particles, LDL clearance, or liver lipid handling. This does not mean the pathway is active or impaired right now; it means the gene can help prioritize what to check next.

What happens when SLCO1B1 is altered

Altered SLCO1B1 signal should be treated as a DNA-based tendency, not a diagnosis. 1 claim currently passes the report-use gate. The useful question is whether symptoms, labs, and lifestyle context line up with the pathway signal.

Curated SNP evidence for SLCO1B1

These SNPs come from the approved study-level evidence model. Each claim is scored from curated study rows, then gated before it can influence pathway scoring.

Evidence-backed report connection

SLCO1B1 currently has 1 curated SNPs, 1 claim-level scores, and 1 claims eligible for pathway scoring.

Open the sample report
rs4149056c.521T>C / V174A1 claims · 1 study rows

transport activity · C

OATP1B1 transport activity

Strong

rs4149056 C is associated with decreased SLCO1B1/OATP1B1 transport activity.

SLCO1B1 rs4149056 C is staged as a reduced hepatic uptake transporter allele with pharmacogenomic and endogenous-substrate context.

Likely effectLower transport signal
Signal sizeModerate signal
Evidence supportModerate support
Report useIncluded in pathway scoring
Show study evidence

Common symptoms people report

  • unexpected cholesterol or triglyceride results
  • family context around lipid markers
  • unclear ApoB, LDL-C, HDL-C, or triglyceride patterns

Biomarkers to validate

ApoB

Shows the number of atherogenic particles more directly than total cholesterol.

LDL-C, HDL-C, and triglycerides

Gives the basic lipid pattern that DNA can help contextualize.

Lp(a) or liver enzymes when relevant

Adds context for inherited lipid risk or liver lipid handling.

Where DNA analysis helps

DNA helps decide whether SLCO1B1 deserves attention inside the broader Lipids pathway. It is most useful when combined with biomarkers instead of used as a standalone answer.

Example interpretation

SLCO1B1 may add context to lipoprotein transport, triglyceride-rich particles, LDL clearance, or liver lipid handling, especially when its SNP evidence lines up with other genes in the same pathway.

Suggested validation: ApoB.

What to do next

  • Review the Lipids pathway result before interpreting SLCO1B1 on its own.
  • Use relevant biomarkers to confirm whether this DNA tendency is visible in current biology.
  • Treat supplement or nutrition decisions as follow-up steps only after the pattern fits symptoms or labs.

Upload your DNA file and receive a structured metabolic pathway analysis with prioritized insights and suggested validation markers.

Get My DNA Report

Related pages